In a recent article by Chijiwa et al.1 , anti-IL-17A antibody (secukinumab; SEC) administration was reported to reduce the elevated levels of serum KL-6 in patients with psoriasis. We have encountered… Click to show full abstract
In a recent article by Chijiwa et al.1 , anti-IL-17A antibody (secukinumab; SEC) administration was reported to reduce the elevated levels of serum KL-6 in patients with psoriasis. We have encountered a unique case of psoriasis vulgaris with increased serum KL-6 levels and paradoxical development of interstitial pneumonia (IP) after the introduction of SEC administration. A 66-year-old male with a 20-year history of psoriasis vulgaris was referred to our department. At initial presentation, multiple scaly erythematous plaques were scattered on the trunk and extremities (Fig. 1a). Blood tests revealed increased serum KL-6 level (1,408 U/mL; normal range <500 U/mL), while surfactant protein-D level was within the normal range. This article is protected by copyright. All rights reserved.
               
Click one of the above tabs to view related content.